Status:
COMPLETED
The Symphony Triple A Study: Using Symphony in Treatment Decisions Concerning Adjuvant Systemic Therapy
Lead Sponsor:
Diakonessenhuis, Utrecht
Collaborating Sponsors:
Agendia
Conditions:
Breastcancer
Invasive Breast Carcinoma by Gene Expression Profile
Eligibility:
FEMALE
18+ years
Brief Summary
Rationale: Prediction of prognosis in patients with breast cancer is important to determine the indication for adjuvant chemo-, endocrine- and immunotherapy. Apart from the clinicopathological parame...
Detailed Description
1. INTRODUCTION AND SCOPE During the last decade treatment guidelines for the administration of adjuvant chemotherapy in patients with breast cancer have changed, today advising chemotherapy in the ma...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Oestrogen receptor positive, invasive ductal and female breast cancer patients where the benefit of adjuvant chemotherapy is uncertain based on traditional prognostic factors
- Written informed consent
- Patients with multicentric or contralateral disease
- Exclusion criteria
- Patients with a previous history of malignancy (in the five years before breast cancer diagnosis), excluding basal cell carcinoma.
- Patients with confirmed distant metastasis.
- Patients who undergo neoadjuvant systemic treatment.
Exclusion
Key Trial Info
Start Date :
January 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2016
Estimated Enrollment :
660 Patients enrolled
Trial Details
Trial ID
NCT02209857
Start Date
January 1 2013
End Date
May 1 2016
Last Update
February 15 2017
Active Locations (34)
Enter a location and click search to find clinical trials sorted by distance.
1
Whilhelmina ziekenhuis
Assen, Drenthe, Netherlands, 9041RK
2
Medisch Centrum Zuiderzee
Lelystad, Flevoland, Netherlands, 8233AA
3
Gelre ziekenhuis
Apeldoorn, Gelderland, Netherlands, 7334 DZ
4
Rijnstate
Arnhem, Gelderland, Netherlands, 6815AD